Mivobulin is primarily utilized in the field of cancer research and treatment. It functions as a microtubule inhibitor, which means it disrupts the formation of microtubules essential for cell division. This property makes it particularly effective in targeting rapidly dividing cancer cells, thereby inhibiting their growth and proliferation. Researchers have explored its potential in various preclinical studies, focusing on its efficacy against different types of tumors. Additionally, mivobulin has been investigated for its ability to enhance the effectiveness of other chemotherapeutic agents, offering a synergistic approach to cancer therapy. Its application extends to studying cellular mechanisms and pathways involved in mitosis, providing valuable insights into cancer biology and potential therapeutic strategies.